Open-Label Assessment of the Effects of Itraconazole and Rifampicin on Balovaptan Pharmacokinetics in Healthy Volunteers

Discovery of Balovaptan, a Vasopressin 1a Receptor Antagonist for the Treatment of Autism Spectrum Disorder

(2020) Patrick Schnider et al.   JOURNAL OF MEDICINAL CHEMISTRY

A phase 2 clinical trial of a vasopressin V1a receptor antagonist shows improved adaptive behaviors in men with autism spectrum disorder

(2019) Federico Bolognani et al.   Science Translational Medicine

P.210 Safety, tolerability, pharmacokinetics and metabolism of balovaptan, a selective vasopressin 1a receptor antagonist, in healthy subjects

(2019) M. Derks et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Autism Spectrum Disorder: Classification, diagnosis and therapy

(2018) Samata R. Sharma et al.   PHARMACOLOGY & THERAPEUTICS

Replicative genetic association study between functional polymorphisms in AVPR1A and social behavior scales of autism spectrum disorder in the Korean population

(2017) So Young Yang et al.   Molecular Autism

The Oxytocin–Vasopressin Pathway in the Context of Love and Fear

(2017) C. Sue Carter   Frontiers in Endocrinology

Epidemiology of autism in adults across age groups and ability levels

(2016) Traolach S. Brugha et al.   BRITISH JOURNAL OF PSYCHIATRY

A Single Dose, Randomized, Controlled Proof-Of-Mechanism Study of a Novel Vasopressin 1a Receptor Antagonist (RG7713) in High-Functioning Adults with Autism Spectrum Disorder

(2016) Daniel Umbricht et al.   NEUROPSYCHOPHARMACOLOGY

Ritonavir is the best alternative to ketoconazole as an index inhibitor of cytochrome P450-3A in drug-drug interaction studies

(2015) David J. Greenblatt et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Psychotropic Medication Use and Polypharmacy in Children With Autism Spectrum Disorders

(2013) D. Spencer et al.   PEDIATRICS

Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation

(2013) Ulrich M. Zanger et al.   PHARMACOLOGY & THERAPEUTICS

Neuromodulation by Oxytocin and Vasopressin

(2012) Ron Stoop   NEURON

Vasopressin V1a and V1b Receptors: From Molecules to Physiological Systems

(2012) Taka-aki Koshimizu et al.   PHYSIOLOGICAL REVIEWS

The effect of grapefruit juice on drug disposition

(2011) Michael J Hanley et al.   Expert Opinion on Drug Metabolism & Toxicology

Oxytocin and vasopressin in the human brain: social neuropeptides for translational medicine

(2011) Andreas Meyer-Lindenberg et al.   NATURE REVIEWS NEUROSCIENCE

Functionality of promoter microsatellites of arginine vasopressin receptor 1A (AVPR1A): implications for autism

(2011) Katherine E Tansey et al.   Molecular Autism

Association study between single nucleotide polymorphisms in promoter region of AVPR1A and Korean autism spectrum disorders

(2010) So Young Yang et al.   NEUROSCIENCE LETTERS

Clinical Relevance of the Pharmacokinetic Interactions of Azole Antifungal Drugs with Other Coadministered Agents

(2009) Roger J. M. Brüggemann et al.   CLINICAL INFECTIOUS DISEASES

Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation

(2008) Ulrich M. Zanger et al.   ANALYTICAL AND BIOANALYTICAL CHEMISTRY

Drugs Behave as Substrates, Inhibitors and Inducers of Human Cytochrome P450 3A4

(2008) Shu-Feng Zhou   CURRENT DRUG METABOLISM